Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Mass General Brigham Ventures

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 29
Average round size
info
The average size of a deal this fund participated in
$57M
Portfolio companies 20
Lead investments 3
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.31
Key employees Soon
Stages of investment
Early Stage Venture

Areas of investment

  • Health Care
  • Biotechnology
  • Therapeutics
  • Medical
  • Hospital

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Mass General Brigham Ventures:
Typical Co-investors
Mass General Brigham Ventures is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Mass General Brigham Ventures:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
ARES International China, Jiangsu, Taiwan
Blue Elephant Capital Beijing, Beijing, China
BtoBfactory Ventures Community of Madrid, Madrid, Spain
Chengdu Technology Transfer Group Chengdu, China, Sichuan
ID Global Corporation New Zealand, Wellington, Wellington
Keyrus France, Ile-de-France, Levallois-perret
Southern Africa Innovation Support -
Syncom Venture Partners Maryland, Silver Spring, United States
Wing Capital Group Milwaukee, United States, Wisconsin

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Rippl Care

Health Care
02 Oct 2024 Seattle, Washington, United States

Tuesday Health

$60M21 May 2024 Nashville, Tennessee, United States

InStride Health

Health Care
$30M27 Mar 2024 Boston, Massachusetts, United States

Nocion Therapeutics

Biotechnology
Health Care
Medical
$62M04 Mar 2024 Cambridge, Massachusetts, United States

Claris Biotherapeutics

Biotechnology
Health Care
Therapeutics
$57M04 Jan 2024 Jersey City, New Jersey, United States

ROME Therapeutics

Biotechnology
Health Care
Pharmaceutical
$72M12 Sep 2023 Cambridge, Massachusetts, United States

Abcuro

Biotechnology
Health Care
Medical
Therapeutics
$155M17 Aug 2023 Newton, Massachusetts, United States

Violet Therapeutics

Health Care
Medical
Therapeutics
$10M05 May 2023 Cambridge, Massachusetts, United States

Mediar Therapeutics

Biotechnology
Therapeutics
$85M15 Mar 2023 Cambridge, Massachusetts, United States
News
Garuda Therapeutics Raises $72M in Series A Financing

– Garuda Therapeutics from Cambridge develops off-the-shelf, durable blood stem cell therapies.
– Series A funding of $72m brings company valuation to more than $1b.
– The round was led by Aisling Capital, Northpond Ventures and Orbimed, supported by Cormorant Asset Management, Ridgeback Capital Investments, Monashee Investment Management, Sectoral Asset Management, National Resilience, Inc. (Resilience), Mass General Brigham Ventures, among others.

Amolyt Pharma Raises $80M in Series B Financing

– Amolyt Pharma from Lyon develops therapeutic peptides for rare endocrine and related diseases.
– The company closed an $80m Series B round.
– The round was co-led by Sectoral Asset Management and Andera Partners, with participation from ATEM Capital, LSP, Novo Holdings (Novo Ventures), Kurma Partners, Mass General Brigham Ventures, Innobio 2 managed by Bpifrance, Orbimed, Pontifax, Eurazeo, Sham Innovation Santé/Turenne Capital and Credit Agricole Creation.
– The company plans to use the proceeds from the financing to advance its pipeline of potential therapeutics for rare endocrine and related diseases, including clinical development of AZP-3601 for hypoparathyroidism, pre-clinical development of AZP-3813 for acromegaly and ongoing research related to AZP-3404, and to further expand its early-stage pipeline through both internal research and development activities and potential in-licensing opportunities.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Mass General Brigham Ventures?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 29
Average round size 57M
Peak activity year 2021
Lead investments 3
Follow on index 0.31
Group Appearance index 0.97

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Rippl Care

Health Care
02 Oct 2024 Seattle, Washington, United States

Tuesday Health

$60M21 May 2024 Nashville, Tennessee, United States

InStride Health

Health Care
$30M27 Mar 2024 Boston, Massachusetts, United States

Nocion Therapeutics

Biotechnology
Health Care
Medical
$62M04 Mar 2024 Cambridge, Massachusetts, United States

Claris Biotherapeutics

Biotechnology
Health Care
Therapeutics
$57M04 Jan 2024 Jersey City, New Jersey, United States

ROME Therapeutics

Biotechnology
Health Care
Pharmaceutical
$72M12 Sep 2023 Cambridge, Massachusetts, United States

Abcuro

Biotechnology
Health Care
Medical
Therapeutics
$155M17 Aug 2023 Newton, Massachusetts, United States

Violet Therapeutics

Health Care
Medical
Therapeutics
$10M05 May 2023 Cambridge, Massachusetts, United States

Mediar Therapeutics

Biotechnology
Therapeutics
$85M15 Mar 2023 Cambridge, Massachusetts, United States
Crunchbase icon

Content report

The following text will be sent to our editors: